A PHASE II TRIAL OF ATEZOLIZUMAB PLUS INDUCTION CHEMOTHERAPY (CT) PLUS CHEMO-RADIOTHERAPY AND ATEZOLIZUMAB MAINTENANCE THERAPY IN NON-RESECTABLE STAGE IIIA-IIIB NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A PHASE II TRIAL OF NEOADJUVANT TREATMENT CARBOPLATIN-PEMETREXED-BEVACIZUMAB PLUS ATEZOLIZUMAB FOR THE TREATMENT OF LOCALLY ADVANCED AND POTENTIALLY RESECTABLE NSCLC PATIENTS WITH EGFR MUTATIONS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS)
Tipus: ASSAIG CLÍNIC Autor: abel lÓpez bermejo Centre: Hospital Universitari Dr.Josep TruetaA phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age.
Tipus: ASSAIG CLÍNIC Autor: antoni castro guardiola Centre: Hospital Universitari Dr.Josep TruetaA Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Tipus: ASSAIG CLÍNIC Autor: josep maria roncero vidal Centre: Institut Català d'Oncologia (ICO)A PHASE III CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY VS CHEMO-IMMUNOTHERAPY FOR STAGE IB-IIIA COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Tipus: ASSAIG CLÍNIC Autor: sonia del barco berron Centre: Institut Català d'Oncologia (ICO)A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
Tipus: ASSAIG CLÍNIC Autor: jordi rubiÓ casadevall Centre: Institut Català d'Oncologia (ICO)A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated METOverexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg
Tipus: ASSAIG CLÍNIC Autor: anna maroto gonzalez Centre: Hospital Universitari Dr.Josep TruetaA prospective single-blind RCT on the effectiveness of quadripolar intravaginal radiofrequency for the treatment of overactive bladder symptoms
Tipus: ASSAIG CLÍNIC Autor: joan melendez muÑoz Centre: Hospital Universitari Dr.Josep TruetaA Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Tipus: ESTUDI OBSERVACIONAL Autor: silvia mauri roca Centre: Hospital Universitari Dr.Josep TruetaA Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A randomized controlled clinical trial to evaluate the MS-LINE! Cognitive rehabilitation program for people with MS
Tipus: ASSAIG CLÍNIC Autor: jordi gich fullÀ Centre: Hospital Universitari Dr.Josep TruetaA Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A RANDOMIZED PHASE II STUDY OF NEO-ADJUVANT CHEMO/IMMUNOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR THE TREATMENT OF LOCALLY ADVANCED AND POTENTIALLY RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse
Tipus: ASSAIG CLÍNIC Autor: Àlvar rosellÓ serrano Centre: Institut Català d'Oncologia (ICO)